Silke Müller Selected Research

1,1'- bis- (4- sulfobutyl)indotricarbocyanine- 5,5'- dicarboxylic acid diglucamide

1/2008

Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silke Müller Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 12/2005
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Leukopenia 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Osteomyelitis 12/2021
1	Reinfection 12/2021
1	Infections 12/2021
1	Diabetes Mellitus 03/2015
1	Obesity 03/2015
1	Inflammation (Inflammations) 02/2013
1	Myocardial Infarction 07/2005
1	Infarction (Infarctions) 07/2005

Drug/Important Bio-Agent (IBA)

1	ChAdOx1 nCoV-19IBA 01/2022
1	EnzymesIBA 01/2022
1	IntegrinsIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	Caspofungin (Cancidas)FDA Link 12/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 03/2015
1	CytokinesIBA 02/2013
1	Bromelains (Bromelain)IBA 02/2013
1	1,1'- bis- (4- sulfobutyl)indotricarbocyanine- 5,5'- dicarboxylic acid diglucamideIBA 01/2008
1	Contrast MediaIBA 01/2008
1	Cytostatic AgentsIBA 12/2005
1	Fibroblast Growth Factor 1 (FGF-1)IBA 07/2005
1	Enoxaparin (Lovenox)FDA LinkGeneric 07/2005

Therapy/Procedure

1	Surgical Amputation (Amputations) 12/2021
1	Arthroplasty 12/2021
1	Disarticulation 12/2021